Novartis adds novel pain program via $200m Spinifex buy
This article was originally published in Scrip
Executive Summary
Executing on its planned strategy for an 'exit' exactly on schedule, Australian/US biotech Spinifex Pharmaceuticals has agreed to be acquired by Novartis for $200m plus undisclosed development and regulatory milestones.